FDA Approves Daraxonrasib for Advanced Pancreatic Cancer
By United One News · AI-generated summary of 4 outlets' reporting
Published · Updated
AI-generated summary of the coverage listed below:
- The U.S. Food and Drug Administration granted accelerated approval to daraxonrasib, a once‑daily targeted therapy for metastatic pancreatic cancer, after a Phase 3 trial demonstrated a nearly doubled survival rate compared with standard treatment.
- The drug works by inhibiting a mutated protein that drives tumor growth.
- The approval offers a new treatment option for patients with this aggressive cancer, potentially improving outcomes and extending life expectancy.
Covered by 4 outlets across the spectrum: 0% left, 75% center, 25% right.
How each side framed it
Pancreatic cancer drug Daraxonrasib gets approval from FDA: All you need to know
FDA Approves Drug For Advanced Pancreatic Cancer; Drug Nearly Doubles Survival In Trial
Left-leaning outlets have under-covered this story. Of 4 outlets, only 0 are on the left of the spectrum.
Timeline
First reported by Hindustan Times on ; 4 articles from 4 outlets so far.
Who is covering this story
- Center (3): Hindustan Times, Mint, Deccan Herald
- Right-leaning (1): Times Now
Sources
- Pancreatic cancer drug Daraxonrasib gets approval from FDA: All you need to know — Hindustan Times (center) ·
- FDA Approves Drug For Advanced Pancreatic Cancer; Drug Nearly Doubles Survival In Trial — Times Now (right-leaning) ·
- US FDA approves landmark pancreatic cancer drug Rasonque: Here's how much will it cost you — Mint (center) ·
- US FDA approves ‘landmark’ pancreatic cancer drug: How far Indians stand in the line? — Deccan Herald (center) ·